National Institute of Genetics Tochitose Group Started partnership to expand database functions to promote utilization of microbiome data
Inter-University Research Institute Corporation Research Organization of Information and Systems National Institute of Genetics (Mishima City, Shizuoka Prefecture; hereinafter referred to as NIG) Chitose Laboratory Co., Ltd. (Kawasaki City, Kanagawa Prefecture; hereinafter referred to as Chitose), the core corporation of the Chitose Group, Tabi will form a partnership with the aim of promoting private sector utilization and social implementation of MicrobeDB.jp (Note 1), an integrated microbial database developed mainly by Professor Akira Kurokawa and Associate Professor Hirofumi Mori. By utilizing the large-scale microbial data accumulated by NIG for analysis services using Chitose’s AI technology and analysis platform (Note 2), we will contribute to the promotion of data utilization in the healthcare industry.
Microbiomes (microbiomes) that exist in the human body and environment are expected to be applied in various fields such as health, beauty, medicine, agriculture, environmental conservation, and mild disorders (Note 3). The number of research papers on the microbiome worldwide exceeds 10,000 per year and is increasing year by year. In order to apply the huge amount of data published accompanying these papers to business development in the industrial world, it is necessary to develop a data infrastructure for accumulating data and an analysis infrastructure for discovering useful knowledge from the data. construction will be required.
Since 2011, NIG has opened MicrobeDB.jp, an integrated microbial database. MicrobeDB.jp automatically collects over 1.6 million samples of microbiome data published in conjunction with research papers around the world, and links it with additional information (metadata) including human health conditions. Well maintained. As a result, in addition to the name of microorganisms, it is a data base with extremely high searchability that can narrow down samples based on metadata such as human age and disease.
In order to contribute to the realization of a prosperous world that will last for a thousand years, Chitose conducts research and development and business development to move from a
consumption-oriented society centered on fossil resources to a recycling-oriented society centered on biomass resources, mainly in Japan and Southeast Asia. I’m here. We have strengths in technology that utilizes “small living things” such as microorganisms, algae, and animal cells, and we have AI technology that automatically controls the cultivation of microorganisms, and data analysis technology and analysis infrastructure that evaluates the abundance of microorganisms in the environment. I have
Through this partnership, it will be possible to handle the data accumulated in MicrobeDB.jp on Chitose’s analysis platform. It is now possible to use it for analysis services such as deriving effective lifestyle habits to arrange biomes.
Furthermore, by expanding the data and functions of MicrobeDB.jp according to the needs that Chitose has extracted from the healthcare industry, Tochitose will be able to make better use of data in the business development of healthcare companies that are Chitose’s customers. I will update it to an easy-to-use base. In the future, we will maximize the utility value of the public resource of academic paper data and connect it to the creation of the healthcare industry based on evidence.
In addition, this partnership is a strategic innovation creation program (SIP) Phase 2 smart bio industry/agricultural basic technology business Chitose and NIG’s efforts for social implementation of large-scale data utilization by private companies. becomes the shape. SIP has collected intestinal microbiome data, physical information, health information, lifestyle habits, and other data from more than 1,000 healthy Japanese individuals. Note 4) is scheduled to be open to the public from 2024. As a result, it will be possible to compare academic paper data in MicrobeDB with data from healthy individuals in SHD, and it is expected to facilitate analysis of relationships between diseases and the microbiome using high-quality public data. (Note 1) MicrobeDB.jp
A database that integrates various microbial information such as genes, strains, and environments, with genome information as the core. Global microbiome data registered in the International Nucleotide Sequence Databases (INSD) are linked with metadata such as disease information and environmental information, and a unified analysis method (analysis pipeline) It is accumulated in a form converted into phylogenetic composition information and functional gene composition information of microorganisms by . This database is being developed and operated by the Genome Evolution Laboratory (Professor Kurokawa) and the Genome Diversity Laboratory (Associate Professor Mori) in the JST NBDC “Integration Promotion Program”.
(Note 2) Chitose’s data analysis platform
Microbiome data in MicrobeDB.jp is acquired through SPARQL endpoints and stored in the Chitose data storage platform built on the cloud environment. The data storage infrastructure is managed in multiple layers of data lake, data warehouse, and data store depending on the aspect and usage of the data. These data can be subjected to machine learning and statistical analysis in a private subnet environment with high confidentiality, and analysis operations can be performed through a command line virtual environment or an analysis UI (user interface) on a browser.
(Note 3) Mild disorder
A mild physical and mental disorder that people subjectively feel. The Japan Self-Care Food Council (https://scfc.or.jp/) promotes product certification as evidence.
(Note 4) SIP Healthcare Group Sharing Database: SHD
-Outline of each institution-
●National Institute of Genetics
As a core research center for genetics, we are conducting advanced research aimed at elucidating life systems. In addition, as an inter-university research institute, we provide a place for joint use and joint research in genetics to academia and industry related to life sciences.
The Chitose Group is a group of biotech companies that lead the world’s bioeconomy. We are cooperating with the government and many companies in order to leave an environment where human beings can live in abundance for the next 1000 years, and deploying technology to society while establishing economic rationality.
◯Overview of CHITOSE BIO EVOLUTION PTE. LTD., which oversees the entire Chitose Group
・Established: October 2011
・Representative: CEO Tomohiro Fujita Ph.D.
◯ Outline of “Chitose Laboratory Co., Ltd.”, which conducts technology development and business development as the core company of the Chitose Group
・Established: November 2002
・Headquarters: Kawasaki City, Kanagawa Prefecture
・Representative: Tomohiro Fujita, Ph.D., Representative Director and CEO / Rie Kugimiya, Representative Director and COO
Details about this release: